Form 4: M33 Growth Entities Divest Over 750,000 Shares of Oncology Institute Stock

M33 Growth I L.P., M33 Growth I GP LLC, and TOI M, LLC, entities associated with a director and 10% owner of The Oncology Institute, Inc., reported the sale of 750,000 shares of common stock for approximately $2.29 million.

Summary

• M33 Growth I L.P., M33 Growth I GP LLC, and TOI M, LLC, all affiliated with a director and 10% owner of The Oncology Institute, Inc. (TOI), reported transactions on June 5, 2025.
• M33 Growth I L.P. directly disposed of 673,676 shares of common stock at a price of $3.05 per share.
• TOI M, LLC indirectly disposed of 76,324 shares of common stock, also at $3.05 per share.
• The total number of shares sold across these entities was 750,000, amounting to a total transaction value of $2,287,500.
• Following these transactions, M33 Growth I L.P. directly holds 13,950,557 shares, and TOI M, LLC indirectly holds 1,272,724 shares, totaling 15,223,281 shares beneficially owned by the reporting group.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant insider selling by a director and 10% owner, which can be interpreted as a lack of confidence in the company's future performance.

Negatives

• Significant insider selling by entities associated with a director and 10% owner, which may signal a lack of confidence in the company's near-term prospects.
• The sale of 750,000 shares represents a substantial divestment by key stakeholders.

Risks

• Insider selling can be perceived negatively by the market, potentially leading to downward pressure on the stock price.
• A large sale by a significant shareholder and director may raise questions about future strategic direction or financial performance.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of insider trading and does not provide broader industry context or trends. It reflects specific investment decisions by a significant shareholder within the healthcare/oncology sector.

Related Party Transactions

• M33 Growth I L.P., M33 Growth I GP LLC, and TOI M, LLC are related entities, with M33 Growth I GP LLC serving as the general partner of M33 Growth I L.P., and Gabriel Ling being a managing member across these entities.
• The transactions involve sales of common stock by these related entities, which are also associated with a director and 10% owner of The Oncology Institute, Inc.

Stakeholder Impact

• Shareholders: May interpret the insider selling as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.

Key Dates

Keywords

Oncology Institute, TOI, M33 Growth, Insider Sale, Form 4, SEC Filing, Stock Transaction, Beneficial Ownership, Director Sale, 10% Owner